You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 10,231,965

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,231,965

Title:	Molecules for administration to ROS1 mutant cancer cells
Abstract:	Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s):	Jonathan Lim, Elena Ardini, Maria Menichincheri
Assignee:	Nerviano Medical Sciences SRL , Ignyta Inc
Application Number:	US14/623,904
Patent Claims:	1. A method of treating cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 2. A method according to claim 1, wherein said at least one target gene is ROS1. 3. A method according to claim 1, wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3. 4. A method according to claim 1, wherein said cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer. 5. A method according to claim 4, wherein said cancer is selected from non-small cell lung cancer, neuroblastoma, and colorectal cancer. 6. A method of treating non-small cell lung cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 7. A method according to claim 1, wherein said cancer is papillary thyroid cancer. 8. A method according to claim 1, wherein said cancer is pancreatic cancer. 9. A method according to claim 1, wherein said cancer is colorectal cancer. 10. A method according to claim 1, wherein said cancer is mammary analogue secretory carcinoma. 11. A method of treating a sarcoma in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 12. A method according to claim 6, wherein said at least one target gene is ROS1. 13. A method according to claim 6, wherein said at least one target gene is NTRK1. 14. A method according to claim 6, wherein said at least one target gene is NTRK2. 15. A method according to claim 6, wherein said at least one target gene is NTRK3. 16. A method according to claim 1, wherein said at least one target gene is NTRK1. 17. A method according to claim 1, wherein said at least one target gene is NTRK2. 18. A method according to claim 1, wherein said at least one target gene is NTRK3. 19. A method according to claim 11, wherein said at least one target gene is ROS1. 20. A method according to claim 11, wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.